Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of GSK2849330 in advanced HER3-positive solid tumors
NL-OMON44080Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of GSK2849330 in melanoma, gastric cancer (GC), esophagogastric junction cancer and 2 more (4 cohorts), sponsored by GSK. Primary endpoint: Adverse events. Started Jun 2015; status: active, not recruiting.
02
Drugs
GSK2849330
03
Conditions
melanomagastric cancer (GC)esophagogastric junction cancerhead and neck cancer (HNC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON44080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44080.